Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Healthy Alaskan.
Press releases published on April 1, 2025
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
GlobeNewswire
·
April 1, 2025
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, …
Hopebridge reflects on 20 years of autism care, addressing growing need for services during World Autism Month
GlobeNewswire
·
April 1, 2025
Indianapolis, April 01, 2025 (GLOBE NEWSWIRE) -- As autism prevalence continues to rise, the importance of education and awareness for the public also continues to grow. In addition to celebrating 20 years of service in 2025, Hopebridge Autism Therapy …
Best Cutting and Bulking SARMS for Muscle Growth and Fat Loss 2025 - Buy Legal SARMS Online from CrazyBulk
GlobeNewswire
·
April 1, 2025
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Looking to transform your physique with the best cutting and bulking SARMs available online in 2025? Selective Androgen Receptor Modulators (SARMs) have become the go-to solution for bodybuilders and fitness …
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
GlobeNewswire
·
April 1, 2025
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of …
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George …
Kraig Biocraft Laboratories Secures Four Registered Trademarks for SpydaSilk® Brand, to Advance Commercialization Strategy for Recombinant Spider Silk
GlobeNewswire
·
April 1, 2025
ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or the "Company"), a world leader in recombinant spider silk technology, today announced that it has secured four registered trademarks for …
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
April 1, 2025
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, …
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
GlobeNewswire
·
April 1, 2025
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of …
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire
·
April 1, 2025
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of …
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
April 1, 2025
FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to …
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
GlobeNewswire
·
April 1, 2025
DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out- …
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session
GlobeNewswire
·
April 1, 2025
124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare …
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire
·
April 1, 2025
PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation …
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
GlobeNewswire
·
April 1, 2025
Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) …
Tonix Pharmaceuticals Launches TONIX ONE™, a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
GlobeNewswire
·
April 1, 2025
CHATHAM, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with a portfolio of marketed products and a pipeline of development candidates, today announced the launch of TONIX ONE™, a …
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
GlobeNewswire
·
April 1, 2025
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025 BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl …
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
GlobeNewswire
·
April 1, 2025
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on …
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
GlobeNewswire
·
April 1, 2025
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in …
Medicenna to Present at Jones Healthcare and Technology Innovation Conference
GlobeNewswire
·
April 1, 2025
TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Codexis Appoints Cynthia Collins to Board of Directors
GlobeNewswire
·
April 1, 2025
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s …